Inferring ecDNA Evolution from Allele Frequency Spectra
En palabras de los autores
Extrachromosomal DNA (ecDNA) can arise early in the development of aggressive tumors or later upon progression, but the impact of chronology on patient outcome is not known. Currently, it is not possible to determine when an ecDNA arose in the course of tumor development and progression, based on genome sequencing data. Here, we develop an analytic method, ecEvol, to infer ecDNA emergence time, selection strength, mutation rate, and clonal dominance from allele frequency spectra in bulk whole-genome sequencing. EcEvol outperforms other methods and predicts parameters with high accuracy across a wide range of parameter values. Applying ecEvol to primary, treatment-naive tumors, we find that ecDNA typically emerges early and undergoes strong positive selection, albeit with substantial variation across cancer types. EcDNAs carrying known oncogenes emerge earlier and reach greater clonal dominance than ecDNAs lacking known oncogenes. In advanced and predominantly treated tumors, ecDNA emerges substantially later than in matched primary tumors, consistent with the generation and selection of new ecDNA during tumor progression and therapy. Longitudinal samples further support continued expansion of ecDNA-bearing lineages. Finally, earlier ecDNA emergence is associated with poorer overall survival. These results provide insight into the chronology of ecDNA formation from a single tumor biopsy taken at any point during the course of the disease, revealing that allele-frequency spectra encode the evolutionary history of ecDNA and provide a quantitative framework for reconstructing its emergence and expansion.
En palabras simples Resumen con IA
Los autores crearon un método llamado ecEvol que estima cuándo el ecDNA apareció por primera vez en un tumor y cómo se propagó. En tumores tempranos no tratados, el ecDNA suele aparecer temprano y propagarse rápidamente debido a una fuerte selección natural. El ecDNA con genes que promueven el cáncer emerge antes y se vuelve más dominante que el ecDNA sin esos genes. Los pacientes cuyo ecDNA apareció antes tienen una supervivencia general peor.
Escrito por Kimi K2.5 usando solo el abstract de arriba. Jev verificó que cada oración esté respaldada por las oraciones del abstract que cita y eliminó las que no. Pasá el cursor por una oración para ver de dónde sale. Se eliminó 1 oración por no estar respaldada por el abstract.
Apareció: lunes, 12 de octubre. bioRxiv. Preprint, todavía sin revisión por pares.